Novo Nordisk’s stock plunges 20% after underwhelming weight-loss trial results for its obesity drug. Analysts say market overreacted.
EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss
